Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
ConvaTec Group PLC is a global medical products and technologies company specializing in chronic care and advanced medical solutions. The company operates primarily in the medical devices and healthcare supplies industries, focusing on products that support patients with chronic conditions and improve clinical outcomes. Its core revenue is driven by consumable medical products used in long-term care settings, hospitals, and home healthcare environments, serving healthcare providers, payers, and patients.
The company’s primary business lines include Advanced Wound Care, Ostomy Care, Continence & Critical Care, and Infusion Care, each addressing distinct but often overlapping patient needs. ConvaTec is positioned as a premium, clinically focused provider with strong brand recognition, recurring revenue from consumables, and high switching costs driven by patient and clinician reliance. The company traces its origins to medical device operations formerly owned by Bristol-Myers Squibb and was established as an independent entity in 2008, later listing on the London Stock Exchange in 2016.
Business Operations
ConvaTec generates revenue through the development, manufacturing, and distribution of single-use and short-term medical products across its four operating segments: Advanced Wound Care, Ostomy Care, Continence & Critical Care, and Infusion Care. Products include wound dressings, ostomy appliances, continence management systems, and infusion devices, with sales driven by volume usage rather than capital equipment purchases. The business model emphasizes long-term patient adherence, clinician education, and reimbursement-supported demand.
Operations are conducted across both domestic and international markets, with manufacturing facilities, R&D centers, and distribution networks spanning multiple regions. The company controls proprietary technologies related to wound healing materials, skin protection, and fluid management systems. ConvaTec operates through numerous wholly owned subsidiaries and maintains commercial relationships with hospitals, group purchasing organizations, distributors, and home healthcare providers rather than relying heavily on joint ventures.
Strategic Position & Investments
ConvaTec’s strategic direction centers on accelerating organic growth, improving operational efficiency, and expanding margins through innovation and portfolio optimization. Growth initiatives include increased investment in R&D, expansion of higher-growth categories such as Infusion Care, and penetration of underdeveloped emerging markets. The company has also focused on pricing discipline and supply chain modernization to strengthen profitability.
Strategic investments and acquisitions have been used selectively to enhance technology capabilities and market access. Notable acquisitions include Triad Life Sciences, which expanded ConvaTec’s biologic wound care offerings, and case study–based digital and service-oriented capabilities supporting patient engagement. The company continues to invest in emerging wound care technologies, skin health solutions, and digitally supported care pathways, while rationalizing lower-growth or non-core assets.
Geographic Footprint
ConvaTec is headquartered in the United Kingdom and operates globally across North America, Europe, Asia-Pacific, Latin America, and parts of the Middle East and Africa. North America represents the company’s largest single market by revenue, driven primarily by the United States healthcare system and reimbursement structure. Europe remains a significant and stable contributor, supported by long-established clinical adoption.
The company maintains manufacturing and R&D operations in multiple countries and sells products in over 90 markets worldwide. International operations play a critical role in long-term growth, particularly in emerging markets where aging populations, rising chronic disease prevalence, and expanding healthcare infrastructure are increasing demand for ConvaTec’s product portfolio.
Leadership & Governance
ConvaTec is led by an executive team with experience across global medical technology, pharmaceuticals, and consumer healthcare. Leadership emphasizes operational excellence, patient-centered innovation, and disciplined capital allocation. The governance structure follows UK public company standards, with a unitary board overseeing strategy, risk management, and executive performance.
Key executives include:
- Karim Bitar – Chief Executive Officer
- Jonathan Lamb – Chief Financial Officer
- Mette Whitfield – President, Ostomy Care
- Nick Francis – President, Advanced Wound Care
- Laurent Dodet – President, Continence & Critical Care
- Toby Taylor – President, Infusion Care
The leadership team’s strategic vision centers on sustainable growth, strengthening core franchises, and advancing clinically differentiated solutions that improve patient outcomes while delivering consistent shareholder value.